Polistes Mastoparan

CAS No. 74129-19-4

Polistes Mastoparan( ——— )

Catalog No. M41359 CAS No. 74129-19-4

Polistes mastoparan is an antimicrobial peptide. Polistes mastoparan increases S. aureus cell K+ efflux and inhibits cell viability with EC50 of 5 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 229 In Stock
10MG 371 In Stock
25MG Get Quote In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock

Biological Information

  • Product Name
    Polistes Mastoparan
  • Note
    Research use only, not for human use.
  • Brief Description
    Polistes mastoparan is an antimicrobial peptide. Polistes mastoparan increases S. aureus cell K+ efflux and inhibits cell viability with EC50 of 5 μM.
  • Description
    Polistes mastoparan is an antimicrobial peptide. Polistes mastoparan increases S. aureus cell K+ efflux and inhibits cell viability with EC50 of 5 μM.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    74129-19-4
  • Formula Weight
    1635
  • Molecular Formula
    C77H127N21O18
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 100 mg/mL (61.16 mM; ultraphonic; )
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Nakao S, et al. Comparative study of the membrane-permeabilizing activities of mastoparans and related histamine-releasing agents in bacteria, erythrocytes, and mast cells. Biochim Biophys Acta. 2011 Jan;1808(1):490-7.?
molnova catalog
related products
  • Elamipretide 2TFA

    Elamipretide is a novel mitochondrion-targeted antioxidant.?Treatment with elamipretide significantly ameliorated LPS-induced learning and memory impairment during behavioral tests.

  • Lumiracoxib

    Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1. Phase 4.

  • Uridine triphosphate

    Uridine triphosphate increases proliferation of human cancerous pancreatic duct epithelial cells by activating P2Y2 receptor.